WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009133522) PIPERIDINE AND PYRROLIDINE COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/133522    International Application No.:    PCT/IB2009/051735
Publication Date: 05.11.2009 International Filing Date: 29.04.2009
IPC:
C07D 211/56 (2006.01), C07D 401/12 (2006.01), C07D 417/14 (2006.01), C07D 471/04 (2006.01), C07D 493/04 (2006.01), A61K 31/4523 (2006.01), A61P 25/00 (2006.01)
Applicants: ACTELION PHARMACEUTICALS LTD [CH/CH]; Gewerbestrasse 16 CH-4123 Allschwil (CH) (For All Designated States Except US).
AISSAOUI, Hamed [FR/FR]; (FR) (For US Only).
BOSS, Christoph [CH/CH]; (CH) (For US Only).
KOBERSTEIN, Ralf [DE/DE]; (DE) (For US Only).
SIEGRIST, Romain [CH/CH]; (CH) (For US Only).
SIFFERLEN, Thierry [FR/FR]; (FR) (For US Only).
TRACHSEL, Daniel [CH/CH]; (CH) (For US Only)
Inventors: AISSAOUI, Hamed; (FR).
BOSS, Christoph; (CH).
KOBERSTEIN, Ralf; (DE).
SIEGRIST, Romain; (CH).
SIFFERLEN, Thierry; (FR).
TRACHSEL, Daniel; (CH)
Agent: SCHAGER, Frank; (CH)
Priority Data:
PCT/IB2008/051673 30.04.2008 IB
Title (EN) PIPERIDINE AND PYRROLIDINE COMPOUNDS
(FR) COMPOSÉS DE PIPÉRIDINE ET DE PYRROLIDINE
Abstract: front page image
(EN)The invention relates to piperidine and pyrrolidine compounds of formula (I) wherein A, B, n and X are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.
(FR)L’invention concerne des composés de pipéridine et de pyrrolidine représentés par la formule (I) dans laquelle A, B, n et X sont tels que décrits dans la description ; des sels pharmaceutiquement acceptables de ceux-ci, et l’utilisation de tels composés en tant médicaments, notamment en tant qu’antagonistes du récepteur de l’orexine.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)